Market Overview

REVA to Hold Second Quarter 2018 Financial Results Call

Share:

SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) ("REVA" or the "Company") has scheduled a conference call to review its second quarter 2018 financial results and provide a business update.

The call is scheduled for 2:30 p.m. PDT on Tuesday, August 7, 2018 (which is 7:30 a.m. AEST on Wednesday, 8 August 2018) and may be accessed within the United States and Canada by dialing 1-877-312-5413 five minutes prior to the scheduled start time. Callers in Australia may access the call toll-free by dialing 1800 005 989. The conference ID is 3186589 for all locations.

If you reside outside of Australia, the United States, or Canada, or if you prefer to access the call through our website, please visit "Events and Presentations" under the "Investors" section of our website at www.revamedical.com, and click on the "listen to webcast" link. A live webcast and transcript of the call will also be available on our website.

About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company's lead products are the Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease. REVA is currently selling Fantom in Germany, Switzerland, Austria, Italy and Turkey. REVA is based in San Diego, California, and employs more than 50 people in the U.S. and Europe.

Fantom and Fantom Encore are trademarks of REVA Medical, Inc.

  United States Australia Australia
  Investor & Media Enquiries: Investor Enquiries: Media Enquiries:
  REVA Medical, Inc. Inteq Limited Buchan Consulting
  Brandi Roberts Kim Jacobs Rebecca Wilson
  Chief Financial Officer +61 438 217 279 +61 3 9866 4722
  +1 858-966-3003

Andrew Cohen
+61 408 333 452
 
  Cheryl Liberatore    
  Director, Communications    
  +1 858-966-3045    
  ir@revamedical.com 

David Schull
Russo Partners
+1 858-717-2310
david.schull@russopartnersllc.com
   

Primary Logo

View Comments and Join the Discussion!